Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03735862 · ClinicalTrials.gov registry record

Complications, Outcomes and Revisions Following Hiatal Hernia Repair With MIROMESH

A clinical trial of Gastroesophageal Reflux and GERD, sponsored by Miromatrix Medical.

Completed
Registry status
85
Enrollment target
1
Study location

NCT03735862: Completed study of Gastroesophageal Reflux and GERD, sponsored by Miromatrix Medical.

NCT03735862 is a study of Gastroesophageal Reflux and GERD that has completed, run by Miromatrix Medical. The registered enrollment target is 85 participants, below the 2,884-participant average among 33 other Gastroesophageal Reflux trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03735862, a study of Gastroesophageal Reflux and GERD, has completed, sponsored by Miromatrix Medical.

COMPLETED
Registry status
85 participants
Enrollment target
1
Study location

Study Summary

Investigator will identify a consecutive cohort of patients who have undergone a hiatal hernia repair and are at least 6 months post index procedure.

Primary Outcome

Patient self-report if they had a revision or other laparoscopic surgery following index procedure.

Interventions

  • BIOLOGICAL Hepatic derived surgical matrix

Study Locations (1)

Virginia

  • Virginia Heartburn and Hernia Institute - Lorton

Trial Details

FieldValue
Enrollment Target 85 participants
Start Date 2017-06-01
Est. Completion 2018-10-01
Miromatrix Medical

4 total trials

What the finished NCT03735862 record still lists

NCT03735862 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 85 participants, a relatively small participant target, below the 2,884-participant average among 33 other Gastroesophageal Reflux trials with a reported enrollment target (97% lower).

The record links to 3 conditions, with Gastroesophageal Reflux appearing as the primary indexed condition, and to 1 intervention - of which Hepatic derived surgical matrix is the first listed.

NCT03735862 reports a single indexed study location in Virginia.

Frequently Asked Questions

What is clinical trial NCT03735862 about?

NCT03735862 is a clinical study titled "Complications, Outcomes and Revisions Following Hiatal Hernia Repair With MIROMESH". Investigator will identify a consecutive cohort of patients who have undergone a hiatal hernia repair and are at least 6 months post index procedure.

What is the current status of trial NCT03735862?

This trial is currently completed. The enrollment target is 85 participants. The study started on 2017-06-01. Estimated completion is 2018-10-01.

What conditions does trial NCT03735862 study?

This clinical trial studies the following conditions: Gastroesophageal Reflux, GERD, Hiatal Hernia With Gastroesophageal Reflux Disease.

What interventions are being tested in trial NCT03735862?

The interventions under investigation include: Hepatic derived surgical matrix (BIOLOGICAL).

Who is sponsoring clinical trial NCT03735862?

This trial is sponsored by Miromatrix Medical, which has 4 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03735862 being conducted?

This trial has 1 study location across Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Gastroesophageal Reflux

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT03735862's enrollment target sits among peer trials

85 17th of 33 higher than 17 of 33 other Gastroesophageal Reflux trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Gastroesophageal Reflux trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00842283 · 85 participants

    Role of Angiogenesis in Dermatologic Diseases: A Potential Therapeutic Target

  • NCT02133196 · 85 participants · Phase 2

    T Cell Receptor Immunotherapy for Patients With Metastatic Non-Small Cell Lung Cancer

  • NCT03823144 · 85 participants · NA

    Intravital Microscopy in Human Solid Tumors

  • NCT03875638 · 85 participants · Phase 2

    Treating Hyperexcitability in AD With Levetiracetam

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT03735862, the US trial registry maintained by the National Library of Medicine. NCT03735862 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.